Articular Gout — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for articular gout. 54 active patents protecting 5 drugs from 3+ originators. First major cliff: 2032. Daily refresh.

5
Approved drugs
54
Active US patents
65/100
Avg vulnerability
—
Annual revenue covered

Originators in Articular Gout

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Schering) 33 patents Casper Pharma Llc 16 patents Pfizer Inc. 5 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating articular gout. Each bar = one year. Y-axis scaled to peak year (7 patents).

5
27
6
28
7
29
2
30
4
31
7
32
4
33
7
34
1
36
3
37
5
39
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Aloprim
ALLOPURINOL
 Casper Pharma Llc 16 63 — 2028-11-26
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Col-Probenecid
probenecid
 Pfizer Inc. 5 76 — 2029-06-03
Deltasone
prednisone
 Generic (originally Schering) 4 76 — 2027-08-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7795243 Col-Probenecid method of use 81 2029-06-03
8168218 Deltasone method of use 80 2028-01-07
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
10183012 Aloprim method of use 75 2028-11-26
10183012 Aloprim method of use 75 2028-11-26
8283369 Aloprim method of use 75 2028-11-26
8283369 Aloprim method of use 75 2028-11-26
8546437 Aloprim method of use 75 2029-04-29

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8546436 Aloprim composition of matter 10 2032-02-29
8546436 Aloprim composition of matter 10 2032-02-29
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
10799642 Decadron formulation 31 2032-05-11
8409606 Decadron formulation 31 2030-05-14
8450287 Decadron formulation 38 2027-12-19
10022502 Decadron method of use 45 2034-06-22
10028965 Decadron method of use 45 2034-05-23
8563027 Decadron method of use 51 2030-02-12

Related